Roche’s Enspryng (satralizumab), a thyroid eye disease (TED) treatment, has been accepted by the FDA and given priority ...

For pharma, its AI progress appears to be slowed by a methodical procession of AI adoption through a series of chicanes.

Oxford BioTherapeutics (OBT) has announced two clinical milestones from its long-running oncology collaboration with ...

Candel Therapeutics has appointed Mark Sims as Chief Commercial Officer, effective 6 July 2026. Sims is a seasoned oncology ...

A single word—manageable—can minimise the real burden of treatment side effects, and it’s time clinical trial communication ...

Strong localisation reduces trial friction, supports site teams, improves participant understanding and helps global studies ...

Patients who had received only one prior line of systemic therapy showed a stronger trend for overall survival and ...

Mental health has been at the centre of our business since our inception. But that work doesn't just extend to our client ...

MRM Health has appointed Hans-Jürgen Wörle to join the Board as an Independent Director. Wörle brings substantial M&A and ...

Genesis Research Group today announced that its EVID AI evidence synthesis platform will be available free of charge through ...

Sanofi’s Cenrifki (tolebrutinib) has been approved by the European Commission to treat secondary progressive multiple ...

AbbVie has announced it will acquire Apogee and its diverse pipeline of multiple clinical-stage candidates in development ...